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Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) has emerged as a major public
health problem in Australia, as in many other parts of the world. High rates of CA-MRSA skin and soft tissue
infection have been reported from Aboriginal communities. We used a single-nucleotide polymorphism (SNP)
genotyping typing system based on the multilocus sequence type (MLST) database to investigate the epide-
miology of CA-MRSA and methicillin-sensitive S. aureus (MSSA) over a 12-month period in three remote
Aboriginal communities of Northern Australia. This was supplemented by real-time PCR for Panton-Valentine
leukocidin (PVL) genes, staphylococcal cassette chromosome mec (SCCmec) typing, and antimicrobial sus-
ceptibility testing. S. aureus was recovered from pyoderma lesions on 221 occasions and throat swabs on 44
occasions. The median monthly recovery rate of S. aureus from skin sores was 58% (interquartile range, 62 to
78%), and there was no seasonal variation. Twenty-three percent of isolates were CA-MRSA; the proportion
was similar across the communities and did not vary over the study period. Erythromycin resistance was found
in 47% of CA-MRSA and 21% of MSSA. SNP-based typing identified 14 different clonal complexes (cc);
however, cc75 was predominant, accounting for 71% of CA-MRSA isolates. These were confirmed as ST75-like
by using an additional SNP and MLST of selected isolates. All but one of the cc75 isolates had SSCmec type
IV (one had type V), and all were PVL negative. Monthly tracking of SNP-based cc types showed a highly
dynamic process. ST75-MRSA-IV appears to be unique to the region and probably evolved de novo in remote
Aboriginal communities.
Methicillin-resistant Staphylococcus aureus (MRSA) was
first recognized as an important nosocomial pathogen in Aus-
tralia in the 1970s (34) and remains a major cause of health-
care-related infection worldwide (2). More recently, commu-
nity-acquired MRSA (CA-MRSA) has emerged as a public
health concern in Australia and elsewhere (9, 14). Classical
healthcare-associated strains (HA-MRSA) tend to be multi-
drug resistant and have staphylococcal chromosomal mec
(SCCmec) type I, II, or III, whereas CA-MRSA strains are
usually not multidrug resistant and possess the smaller and
potentially more mobile SCCmec type IV or V (1, 22). The
genetic background of CA-MRSA usually reflects local geno-
types (42), although some successful clones can rapidly spread
across continents and even across the globe (27). Most strains
of HA-MRSA fall into five broad lineages that are responsible
for the majority of infections worldwide (38). Infections due to
CA-MRSA can be seen in hospital settings, with occasional
major outbreaks (4, 7), while HA-MRSA strains are also able
to circulate within communities (32).
Methicillin resistance in the community setting probably
arises de novo and is, for the most part, independent of the
hospital reservoir. Methicillin-sensitive strains are likely to ac-
quire the mecA gene from other sources, such as coagulase-
negative staphylococci (38). Evidence suggests that this hap-
pens more frequently than previously thought (13) and is more
likely in populations with substantial organism burdens asso-
ciated with domestic crowding, often with frequent staphylo-
coccal skin infection. High rates of CA-MRSA infection have
been reported in people from Aboriginal communities in both
North America and Australia (16, 24, 39, 43), with a reported
spectrum of disease from mild to life-threatening (29). Many
strains of CA-MRSA also have the virulence factor Panton-
Valentine leukocidin (PVL), which has been associated with
skin and soft tissue infection as well as necrotizing pneumonia
and septic shock (8, 35, 42). In Australia, the presence of the
PVL determinant is uncommon in Western Australian CA-
MRSA clones but is found in those derived from the southwest
Pacific and southern Queensland (28, 32).
The epidemiology of CA-MRSA and methicillin-sensitive
Staphylococcus aureus (MSSA) in defined communities has
been investigated to some extent, but most reports are hospital
based or laboratory based and there are few community-based
longitudinal studies. There has also been a lack of effective and
standardized typing methods. For example, phenotyping using
antimicrobial susceptibility patterns (antibiogram) has limita-
tions, not the least of which is the mobility of resistance genes.
Phage typing and pulsed-field gel electrophoresis (PFGE) are
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useful for investigating hospital outbreaks and have been used
in longitudinal studies, but they do not lend themselves to the
study of the genetic evolution of CA-MRSA. PFGE also has
difficulties in achieving interlaboratory agreement. Multilocus
sequence typing (MLST) uses recognized sequences in seven
relatively stable housekeeping genes and is ideal for this pur-
pose (12), especially when combined with typing of SCCmec. A
major drawback is the workload and expense of MLST, making
it available to only well-resourced laboratories.
An alternative approach is to use analysis of a specific set of
single-nucleotide polymorphisms (SNPs) derived from an
MLST database. This method has a high resolving power that
can determine clonal complexes (cc) corresponding to the ma-
jor staphylococcal lineages (40). When SNP-based typing by
real-time PCR is combined with determination of specific vir-
ulence genes, such as those for PVL, it is both cost-effective
and relatively rapid (37).
Previously, Robertson et al. (37) described a method that
used the “Minimum SNPs” software to derive highly informa-
tive SNPs from DNA sequence alignments. We used SNP-
based MLST clonal complex typing to explore the epidemiol-
ogy of MRSA and MSSA over a 12-month period in remote
Aboriginal communities of the Northern Territory (NT), Aus-
tralia. This was combined with real-time PCR for PVL deter-
minants, SCCmec typing of selected isolates, and antimicrobial
susceptibility testing. We specifically set out to document the
prevalence of CA-MRSA in these communities and to charac-
terize changes in the S. aureus population over time. To our
knowledge, it is the first time such a longitudinal study has
been reported and the first time this technology has been used
for community epidemiological investigation.
MATERIALS AND METHODS
Study sites. The study was conducted in three large remote communities in the
tropical Top End of the NT and was part of a larger prospective study of skin and
throat infection in relation to acute rheumatic fever (25). The approximate
community populations were 2,500 (community 1), 800 (community 2), and 1,800
(community 3). Approval was granted by the regional ethics committee prior to
community consultation. Informed consent was obtained from the occupants of
49 study households. We then visited households on a monthly basis to conduct
surveillance for pyoderma, pharyngitis, and acute rheumatic fever. Throat swabs
were taken from every person, those with and without symptoms of pharyngitis,
and skin sore swabs (maximum of three) were taken from all adults and children
with pyoderma. Additional demographic information was collected, including
past history of acute rheumatic fever/rheumatic heart disease, general skin
health, and household size (number of people per bedroom); a detailed analysis
of this information is contained in another paper (26).
Recovering S. aureus isolates. During the period May 2004 to June 2005, S.
aureus isolates were specifically identified and characterized from swabs of all
people with pyoderma. However, S. aureus isolates were only identified and
characterized from throat swabs taken over a 2-month period (June and July
2004). Swabs were struck out on horse blood agar culture plates (Oxoid) in the
community health centers or sealed in airtight bags with desiccant for transpor-
tation back to the laboratory in Darwin, Australia, by aircraft (25). Plates were
incubated at 37°C and inspected at 24 h and 48 h. S. aureus was identified by
colonial morphology and a latex slide agglutination test for detection of clumping
factor, protein A, and specific capsular polysaccharides (Staphytect Plus; Oxoid).
One representative colony per plate was stored in glycerol for further analysis.
Antimicrobial susceptibility testing. Susceptibility testing was performed by
disk diffusion using CLSI (formerly NCCLS) methodology (31). Resistance was
determined by CLSI susceptibility breakpoints (3), and plates were read with an
optical analyzer system (Biomic vision; Giles Scientific, Inc., California). A disk
approximation test was used to detect inducible clindamycin resistance (3). S.
aureus isolates that were resistant to cefoxitin by disk diffusion were tested for the
presence of specific penicillin binding protein (PBP2) using a latex agglutination
test (Oxoid).
DNA extraction. Isolates were plated from glycerol stocks onto horse blood
agar plates and incubated at 37°C overnight. A single colony was picked into 5 ml
of Todd-Hewitt broth (Oxoid) supplemented with yeast and grown at 37°C
overnight with agitation. DNA was extracted from 1 ml of pelleted bacterial cells
using a QIAGEN QIAamp DNA mini kit according to the manufacturer’s
instructions, using 100 g/ml lysostaphin (Sigma). The DNA was eluted in 200 l
of 10 mM Tris, 0.5 mM EDTA, pH 9, and stored at 20°C.
Clonal complex, nucA, and PVL determination. MLST-derived clonal com-
plexes using SNP sets were determined using a single-tube kinetic PCR method
as described by Huygens et al. (17). The primers used in this study are shown in
Table 1. A kinetic PCR uses the SNP at the 3 end of the primer and ascertains
the rate of appearance of the reaction product. SNP tpi36 was included as an
internal control and used to calculate the change in cycle threshold.
Real-time PCR was carried out using a Corbett Rotorgene 2000. Reaction
mixtures contained 1 l of a 1:10 dilution of extracted DNA, 1 SYBR green
PCR MasterMix (Applied Biosystems), and 0.4 M concentrations of each
primer in a total volume of 10 l. Cycling conditions consisted of 50°C for 1 min
and 95°C for 2 min, followed by 40 cycles of 95°C for 5 s, 56°C for 20 s, and 72°C
for 35 s. Isolates assigned to cc93 were typed with an additional SNP (aroE252)
to determine if they were of sequence type 93 (ST93). In addition, all of the
isolates assigned to cc75 were typed with an additional SNP, gmk159G, to
determine their relatedness to ST75. Real-time PCR was also used to verify the
identity of S. aureus isolates by confirming the presence of the nucA gene (23)
and to check for the presence of PVL determinants (40).
Identification of SCCmec type IV and V. The presence of the MS domain of
the mecR1 gene, present in mec gene complexes of type A, B, C1, or D, was
determined using primers mcR3 and mcR4. Isolates positive for this region were
tested for a class B mec gene complex using the primers IS5 and mA6. Isolates
negative for this region were tested with the primers mA1 and mA2 to confirm
the presence of the mecA gene and primers mA2 and IS2 for detection of a class
C2 mec gene complex. Isolates were also tested for the presence of a type 1, 2,
or 3 ccr gene complex using the primers c and c and then specifically for a type
2 ccr gene complex using primers c and 2. Isolates that did not have a type 1,
2, or 3 ccr gene complex were tested with primers specific for the ccrC gene using
primers F and R (19).
SCCmec typing amplification was performed using 1 l of a 1:10 dilution of
template DNA in a 25-l reaction mixture containing 1 PCR buffer, 1 l of
each primer, 200 M deoxynucleoside triphosphates, and 1 U QIAGEN Taq
polymerase. Cycling for all primers consisted of an initial denaturation of 94°C
for 1 min followed by 35 cycles at 94°C for 30 s, 50°C for 30 s, and 72°C for 2 min.
MLST of specific isolates. MLST was performed on five selected isolates as
specified by Enright et al. (11). The sequences obtained were compared with
sequences at the MLST web site at http://www.mlst.net to assign an ST.
Analysis. Laboratory data were compared to the MLST database (http:
//saureus.mlst.net) using a specific computer program (18, 40). Epidemiological
data were analyzed using Stata 9 (Stata Corporation, College Station, Texas).
Differences in proportions were compared with chi-square analysis.
RESULTS
S. aureus and pyoderma. Over the study period, there were
429 household visits, mostly in community 1 and community 3.
There were logistic problems maintaining the project in com-
munity 2, and surveillance was ceased after only 28 household
visits. Skin infection was common, and 38% of children 	15
years had pyoderma on at least one occasion. S. aureus was
recovered from skin sores in 221 of 375 children with pyo-
derma (59%) and was found in company with group A beta-
hemolytic streptococcus on 110 occasions (29%). The median
monthly recovery rate of S. aureus from skin sore swabs was
58% (interquartile range, 62 to 78%), and there was no signif-
icant difference in recovery rates between the wet season (No-
vember to April) and dry season (May to October). On 21
occasions, S. aureus was recovered from multiple pyoderma
lesions from a child on the same day. There were 44 additional
isolates of S. aureus from 513 throat swabs (8.6%) taken over
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a 2-month period; these were presumably related to nasal
carriage.
Antibiotic resistance patterns. PBP2 (methicillin resistance)
was detected in 23% (66 of 283) of isolates (Table 2): 22%
(40/184) in community 1, 30% (3/10) in community 2, and 26%
(23/89) in community 3. The rates did not vary substantially
over the period of the study. PBP2 was detected in 21% (51 of
239) of skin isolates and 34% (15 of 44) of throat isolates. Six
isolates (2%) were susceptible to all the antibiotics in the
panel, including penicillin. A further 164 isolates (58%) were
resistant to penicillin alone, and the remaining 113 (40%) were
resistant to multiple agents (Fig. 1). Erythromycin resistance
was detected in 47% (31/66) of methicillin-resistant isolates
and 21% (46/217) of methicillin-sensitive isolates. Likewise,
44% (29/66) of methicillin-resistant isolates were resistant to
clindamycin, as were 19% (41/217) of methicillin-sensitive iso-
lates. Thirty-three of the MRSA isolates (50%) were resistant
only to beta-lactam antibiotics. The antibiogram showed no
cotrimoxazole-, tetracycline-, gentamicin-, or rifampin-resis-
tant isolates, a pattern typical of CA-MRSA. The throat
MRSA carriage rate of 3% (15 of 513) in this study probably
reflected a substantially higher nasal carriage rate.
SNP typing and presence of PVL. A total of 283 isolates
were SNP typed and assigned to 14 different clonal complexes
(Fig. 2). A unique and dominant clonal complex was initially
identified as cc49 because of highly aberrant alleles. These
TABLE 1. Primers used for SNP typing, PVL and NucA gene detection, and for SCCmec typing
Description Primer name Nucleotide sequence (5–3) Reference
SNP primers
arc162 arcC162_99FL CAGGGTATGATAGGCTATTGGTTG 17
arcC162cAR GATCATCTTTATCTACTTCCACACGTGCT 17
arcC210 arcC210_99FL CAGGGTATGATAGGCTATTGGTTG 17
arcC210RCC CGTATAAAAAGGACCAATTGGTCTG 37
gmk318 gmk318F TGCGTGAAGGTGAAGTTGATG 17
gmk318aTR ACCTACTAATCGCTCTCTCAAGTAA 17
pta294 pta294_411RL CCTTGTGAATCAAGTTCTGGATTG 17
pta294aAF TGCAGCACATTCAACAGAA 17
pta383 pta383_142FL CTGCGACAAGTGAATTGAAAGCTG 17
pta383CT TTGCACAATCACCAAAGATGTATTGCA 17
tpi36 tpi36_206RL TTGATGATTTACCAGTTCCGATTG 17
tpi36cCF GATGAAGAAATTAACAAAAAAGCGCCC 17
tpi36cTF GATGAAGAAATTAACAAAAAAGCGCCT 17
tpi241/3 tpi_365RL GCCCCATCAATATCAGTTTGTG 17
tpi241  243GTA GTAAATCATCAACATCTGAAGATGTA 17
aroE252 aroE 252GF GGTATAATACAGATGGTATCGGTTATGTG 17
aroE 252GR ACCTGCGCCCAAAATTAAAA 17
gmk159G gmk159GF GATGATCAATTTATAGAATATGCCGAG This study
gmk159GR TCGTCCATAGTATCTTTAACATATTGAACTG This study
PVL gene PVLlukFor TATCTCTAACGGCTTGTCAGGTG 17
PVLlukRev TGCTTCAACATCCCAACCAA 17
NucA gene nucAFor GCGATTGATGGTGATACGGTT 23
nucARev AGCCAAGCCTTGACGAACTAAAGC 23
CCR gene complex
Types 1, 2, 3 c ATTGCCTTGATAATAGCCITCT 33
c ATCTATTTCAAAAATGAACCA 33
Type 2 2 (used with c) TAAAGGCATCAATGCACAAACACT 33
ccrC gene F CGTCTATTACAAGATGTTAAGGATAAT 19
R CCTTTATAGACTGGATTATTCAAAATAT 19
mec gene complex
mecR1 (MS domain) mcR4 GTCGTTCATTAAGATATGACG 33
mcR3 GTCTCCACGTTAATTCCATT 33
mecA mA1 TGCTATCCACCCTCAAACAGG 33
mA2 AACGTTGTAACCACCCCAAGA 33
Class B IS5 AACGCCACTCATAACATATGGAA 33
mA6 TATACCAAACCCGACAAC 33
Class C IS2 (used with mA2) TGAGGTTATTCAGATATTTCGATGT 33
TABLE 2. Antibiotic susceptibility profile of 283 community
isolates of S. aureus
Antimicrobial
agent
No. (%) of
isolates resistant
Penicillin....................................................................................277 (98)
Methicillin (PBP2 positive)..................................................... 66 (23)
Erythromycin ............................................................................ 77 (27)
Clindamycin .............................................................................. 70 (25)
Cotrimoxazole........................................................................... 0 (0)
Chloramphenicol ...................................................................... 6 (2)
Gentamicin................................................................................ 0 (0)
Ciprofloxacin............................................................................. 2 (1)
Rifampin ................................................................................... 0 (0)
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isolates were subsequently confirmed as belonging to ST75
using data from an additional SNP (gmk159G) and 5 of the
isolates that were typed by MLST. This clonal complex ac-
counted for 25% (72 of 283) of all S. aureus isolates and 71%
of CA-MRSA (47 of 66) isolates. The cc75 isolates were found
in communities 1 (20% of isolates) and 3 (38% of isolates) but
were not concentrated in particular households. We demon-
strated that cc75 was resistant to more antibiotics on the panel
than other clonal complexes (Fig. 1). Thirty-four of 72 cc75
isolates (47%) were resistant to erythromycin, compared to 43
of the remaining 211 staphylococcal isolates (20%) (P 

	0.0001).
Thirty-nine isolates (14%) belonged to cc93, and typing with
an additional SNP showed them to be ST93. A single cc93
isolate was methicillin resistant, indicating that it was ST93-
MRSA-IV, also known as the Queensland clone. Most of the
remaining CA-MRSA isolates belonged to cc1, the most im-
portant member being ST1-MRSA-IV or WA MRSA-1, or to
cc30. ST30-MRSA-IV is the southwest Pacific clone (1).
Monthly fluctuations of the three most common clonal com-
plexes recovered from pyoderma lesions in communities 1 and
3 are shown in Fig. 3. It can be seen that the month-to-month
prevalence of pyoderma is variable and organisms of specific
lineages ebb and flow in each community as part of a highly
dynamic process. Using the SNP typing data, it was also shown
that on only 4 occasions, organisms of the same clonal complex
were recovered from two or more different lesions on the same
person; while on 15 occasions, they were from different clonal
complexes. One child had isolates of cc6 (MSSA), cc45
(MSSA), and cc75 (MRSA) on three separate, but concurrent,
skin sores.
The genes for PVL were found in organisms of only two
clonal complexes: the four cc30 isolates and 14 (41%) of the
cc93 isolates. None of the cc75 isolates were positive for PVL
(Fig. 4). Of the skin isolates, 19 (8%) were PVL positive,
compared to 1 of 44 throat isolates (2%), although the differ-
ence was not statistically significant (P 
 0.16).
SCCmec allotyping. CA-MRSA usually carries type IV SCCmec
that consists of a class B mec gene complex and a type 2 ccr
gene complex (33). CA-MRSA isolates assigned to cc75 were
tested by PCR for products indicative of a class B mec gene
complex and a type 2 ccr gene complex. All but one was found
to have SCCmec type IV. No product was obtained for the MS
FIG. 1. Antibiotic resistance profile of 283 S. aureus isolates show-
ing that isolates of cc75 tend to be resistant to more antibiotics than the
total pool.
FIG. 2. Distribution of SNP-determined clonal complexes and methicillin resistance in 283 isolates of S. aureus from remote communities.
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domain of the mecR1 gene in the remaining isolate, indicating
that it was likely to contain a class C2 mec gene complex,
typical of type V SCCmec. This was established with primers
specific for class C2. The isolate also failed to provide a prod-
uct indicative of a ccr gene complex of types 1, 2, and 3.
However, it was shown to contain a ccrC gene, using the prim-
ers F and R, confirming it as having SCCmec type V.
MLST results. Five isolates were selected from the most
common SNP profile group. These isolates were found to
closely match ST75 on the MLST database, with variations in
2 of the 7 genes. Variations in allele sequences were found for
arcC and pta loci in four of five isolates. MLST sequencing of
these isolates proved to be problematic because alleles at the
aroE, glpF, and yqiL loci were far removed from other known
alleles at these loci. ST-75 appears to be phylogenetically re-
mote from other S. aureus isolates. The great majority of S.
aureus MLST alleles are 97% similar or greater. However, the
similarity of ST-75 alleles with other alleles ranges from 90 to
95%. The only exception to this is the aroE3 allele. This is
common in the database and very similar to other alleles. Our
current model is that ST-75 diverged from other S. aureus
clones much earlier than the major clones diverged from each
other, but there has been one recent horizontal gene transfer
event that resulted in the common aroE3 allele being intro-
duced into the clone.
DISCUSSION
Most CA-MRSA infections that occur in communities are
skin and soft tissue infections; occasionally they can be severe,
resulting in necrotizing pneumonia and septicemia (29, 35).
Endemic CA-MRSA also has the potential for repeated intro-
duction into the healthcare setting (7, 21). To our knowledge,
there have been no previously published longitudinal studies of
FIG. 3. Monthly fluctuations of pyoderma and skin swabs in communities 1 and 3 showing the three most common S aureus clonal complexes,
as determined by SNP sets. Community visits were restricted in August 2004 and March 2005 for ceremonial reasons.
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methicillin resistance in CA-MSSA infections in Australian
Aboriginal or even non-Aboriginal communities. The findings
are disquieting, with 23% of the isolates being methicillin re-
sistant, and have important implications for future antibiotic
prescribing guidelines in the region and across tropical Aus-
tralia. Likewise, the high rates of resistance to erythromycin
and clindamycin give little cause for comfort.
Reports from Western Australian more than 20 years ago
were among the first in the world to raise the alarm about
CA-MRSA (41). These Western Australian strains have sub-
sequently spread to other parts of the country and beyond (14).
Important clonal groups of MRSA in Australia now include
the Western Australian group (primarily cc1 also called WA
MRSA), the Southwest Pacific group (cc30), the Queensland
group (cc93), the United Kingdom EMRSA-15 (cc22), and
the so-called East Coast clonal group, AUS-2/AUS-3 (cc239)
(1, 14).
The predominant CA-MRSA cc type found in the Aborigi-
nal communities of the Top End was cc75, accounting for 71%
if isolates. This clonal complex does not belong to any of the
previously described clonal groups and appears to stand alone.
It also lacks the genes for PVL. The additional specific SNP
(gmk159G) and MLST sequencing confirmed relatedness to
ST75. ST75-MRSA-IV has appeared in a previous report from
Western Australia (5), and two of these isolates are repre-
sented on the current MLST database. However, on further
investigation, it appears the isolates in the report, and on the
database, actually came from patients in communities of the
Top End of the Northern Territory (Frances O’Brien, personal
communication). It is likely that ST75-MRSA-IV is unique to
the region with CA-MRSA evolving de novo in these commu-
nities, just as it has done in Western Australia.
Increasing rates of CA-MRSA were recognized in Darwin in
the early 1990s (24), and the trend has continued (29), with
most of the infections occurring in the Aboriginal population.
At the Royal Darwin Hospital, the rate of CA-MRSA as a
proportion of S. aureus sepsis increased from 9% in 1998 to
20% in 2001 (10). The majority are typical CA-MRSA strains
that are not multiresistant and have SCCmec type IV (29); this
corresponds with the findings of this study where multiresistant
strains were not encountered. The Top End of the Northern
Territory has about the same area as the US state of Texas, and
the communities in this study are truly remote. Yet, there is a
relatively frequent movement of people between the commu-
nities and the capital city, Darwin, and from community to
community. This includes people traveling for health reasons,
many of whom are admitted to Darwin’s only large public
hospital. There is potential for taking HA-MRSA back to com-
munities, just as CA-MRSA is frequently transmitted to the
hospital environment (24). Yet, in this study, typical HA-
MRSA strains were not found in the Aboriginal communities.
The finding that 21% of S. aureus isolates from skin infection
were CA-MRSA is one of the highest rates reported. The
proportion of CA-MRSA associated with skin infection rose
fourfold, from 4% to 17%, over 3 years in Frejus, France (8),
and accounted for 11% of pyoderma in a recent study from
Southern India (30). Extremely high rates, 55% of all S. aureus
infection, have been reported in one Native American com-
munity (16), and an extended community outbreak has been
reported in South Texas, with frequent cases of cellulitis and
abscesses (36). A recent large study in Atlanta, Georgia, found
that the CA-MRSA clone USA 300 had become the predom-
inant cause of skin and soft tissue infection in the region (20).
There are more than a dozen published community MRSA
nasal carriage studies with rates varying from	1% in Italy (44)
to 9.2% in the southern United States (6). A recent national
study in the United States found an MRSA carriage rate of
0.84% (15). In our study of remote communities, the MRSA
throat carriage rate of 3% (15 of 513) probably reflects a much
higher nasal carriage rate.
The surprise finding of cc75 (ST75) in communities 1 and 3
highlights the regional nature of CA-MRSA. However, the
FIG. 4. Distribution of PVL genes within the clonal complexes.
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communities are more than 400 km apart and in opposite
directions from the regional capital of Darwin. They have
markedly different languages and cultural backgrounds, and
there is limited interaction between them. As distinct from
HA-MRSA, CA-MRSA strains are more likely to reflect pre-
existing regional S. aureus lineages with local acquisition of
SCCmec type IV or V (38). Indeed both MRSA and MSSA
cc75 were shown to be widely circulating in these communities.
Our study shows that the community profile of clonal groups
was highly dynamic; moreover, different strains were often
present on adjacent pyoderma lesions. One of the study limi-
tations was that only one colony was chosen for analysis from
each culture plate, where there may have been multiple types
infecting the same wound. The SCCmec gene was restricted to
but a few clonal groups, and the overall proportion of MRSA
isolates was stable over the study period. Could SCCmec be-
come more mobile across clonal groups with increased com-
munity antibiotic prescribing pressure? This is a question that
requires urgent investigation.
MLST itself is based upon arbitrary gene fragments and
would give significantly different results if different gene frag-
ments were used. The SNP method gives a portable and un-
ambiguous genotype that is of sufficient resolution for an initial
screen of a large number of isolates and also is compatible with
MLST data. The resolution can easily be increased by interro-
gating binary markers (17, 40) and adding an additional SNP.
Isolates that appear interesting can be further characterized by
full MLST, as was done in this study. This approach led to the
identification of a new numerically dominant clone, an impor-
tant epidemiological finding. The SNP genotyping method is
simple and relatively inexpensive when compared to other typ-
ing methods such as MLST and PFGE. It can also be used to
study the epidemiology of MRSA in other settings and even
other microorganisms, such as Streptococcus pyogenes (37). An
understanding of community acquisition and transmission
should lead to more enlightened interventions aimed at treat-
ment and prevention of CA-MRSA infection.
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